Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Director Andrew Regan Sells 35,923 Shares

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Director Andrew Regan sold 35,923 shares of the firm’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $0.51, for a total transaction of $18,320.73. Following the completion of the transaction, the director now directly owns 15,441,772 shares of the company’s stock, valued at approximately $7,875,303.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Andrew Regan also recently made the following trade(s):

• On Wednesday, July 17th, Andrew Regan sold 1,514,100 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.26, for a total value of $393,666.00.
• On Monday, July 15th, Andrew Regan sold 1,005,200 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.25, for a total value of $251,300.00.
• On Friday, July 12th, Andrew Regan sold 1,389,820 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.25, for a total value of $347,455.00.
• On Wednesday, July 10th, Andrew Regan sold 150,000 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.33, for a total value of $49,500.00.
• On Wednesday, July 3rd, Andrew Regan sold 1,000 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.64, for a total transaction of $640.00.

Conduit Pharmaceuticals Stock Up 4.0 %

Shares of CDT opened at $0.14 on Friday. The business’s 50-day moving average is $0.17 and its two-hundred day moving average is $1.77. Conduit Pharmaceuticals Inc. has a fifty-two week low of $0.11 and a fifty-two week high of $22.00.

Conduit Pharmaceuticals (NASDAQ:CDT) last issued its earnings results on Monday, August 12th. The company reported ($0.07) EPS for the quarter.

Analysts Set New Price Targets

Separately, Berenberg Bank raised shares of Conduit Pharmaceuticals to a “strong-buy” rating in a report on Friday, July 26th.

Conduit Pharmaceuticals Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.